Clinical Trial Update: Neoadjuvant Chemoimmunotherapy or Chemoradiotherapy in ESCC [Phase 2]

View source ↗

Summary

Phase 2 trial exploring neoadjuvant chemoimmunotherapy or chemoradiotherapy for resectable esophageal squamous cell carcinoma; status is NOT_YET_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Snippet

Sponsor: Ji Yongling | Conditions: Resectable Esophageal Cancer | Phase 2 | Status: NOT_YET_RECRUITING